SALL2 and cancer: Herein, we found that SALL2 was significantly downregulated during tamoxifen therapy, and loss of SALL2 conferred estrogen‐independent growth and tamoxifen‐resistant phenotype in ER+ cancer cells by decreasing ERα and PTEN expression.